Sitagliptin vs Medroxyprogesterone: side-by-side comparison
Sitagliptin (DPP-4 inhibitor) and Medroxyprogesterone (Progestin) belong to different therapeutic classes and are rarely substitutes for each other. The comparison is useful when a single patient is weighing both options for adjacent or overlapping needs.
| Property | Sitagliptin | Medroxyprogesterone |
|---|---|---|
| Therapeutic class | DPP-4 inhibitor | Progestin |
| CAS | 486460-32-6 | 520-85-4 |
| ATC | A10BH01 | G03DA02 |
| Molecular weight | 407.31 g/mol | 344.49 g/mol |
| Brands with this active ingredient | 1 | 1 |
What they share
Sitagliptin and Medroxyprogesterone share the common regulatory framework for prescription active ingredients, bioequivalence standards for generics, and pharmacist oversight. Beyond that, points in common are limited.
Key differences
Sitagliptin acts by a different mechanism than Medroxyprogesterone, with indications that barely overlap. Comparing the two is useful when a clinician has mentioned both in the same context or the patient wants to understand why one was prescribed instead of the other.
Mechanisms compared
Sitagliptin: La sitagliptine inhibe de façon réversible la DPP-4, sérine protéase responsable de la dégradation rapide du glucagon-like peptide 1 (GLP-1) et du polypeptide insulinotrope glucose-dépendant (GIP). Medroxyprogesterone: La médroxyprogestérone se lie aux récepteurs de la progestérone et exerce de puissants effets progestatifs : épaississement de la glaire cervicale, inhibition de l'ovulation, amincissement de l'endomètre et réduction des…
Indications compared
Sitagliptin: La sitagliptine est autorisée chez l'adulte atteint de diabète de type 2, seule ou en association à d'autres antidiabétiques, pour améliorer le contrôle glycémique. Medroxyprogesterone: La médroxyprogestérone est autorisée dans l'aménorrhée, les saignements utérins anormaux d'origine hormonale, la prévention de l'hyperplasie endométriale chez la femme ménopausée recevant un estrogène, et la prévention d…
Safety profile
Sitagliptin: La sitagliptine est généralement bien tolérée. Medroxyprogesterone: Les effets indésirables fréquents de la forme orale comprennent saignements irréguliers, tension mammaire, variations de l'humeur, rétention hydrique et prise de poids.
Questions fréquentes
Is Sitagliptin better than Medroxyprogesterone? ▾
Sitagliptin and Medroxyprogesterone are not "better or worse" — they treat different things. The sensible question is which fits your specific need.
Can Sitagliptin and Medroxyprogesterone be combined? ▾
Whether they can be combined depends on the indications and the interaction profile of each. If both are in a single prescription, the prescriber has weighed it; in self-medication they should never be combined.
Do they have the same side-effect profile? ▾
No — they belong to different classes and have distinct side-effect profiles. Each has its own prescribing information.
Products with Sitagliptin
Products with Medroxyprogesterone
Les informations publiées sur ce site sont fournies à titre documentaire et pédagogique. Elles ne remplacent pas l'avis d'un professionnel de santé qualifié.